Yixuan Yang

Yixuan Yang

Auto-generated profile, based on publicly available information

Yixuan Yang

College of Life Sciences Nanjing Agricultural University Nanjing 210095 China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2026 in Journal of Integrative Plant Biology
Verified
Journal Article
Closed access
YYYixuan Yang
Yixuan Yang
JHJunqi Hou
Junqi Hou
YWYuanli Wang
Yuanli Wang
LZLibo Zhang
Libo Zhang
JHJinyu He
Jinyu He
MCMing Chang
Ming Chang

12 November 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XXXiaoxia Xing
Xiaoxia Xing
ZZZhihao Zhang
Zhihao Zhang
LLLongxia Li
Longxia Li
ZSZhouying Shen
Zhouying Shen
BXBuri Xi
Buri Xi
YZYiyan Zheng
Yiyan Zheng
Nuclear F-actin facilitates DNA damage repair and contributes to cancer chemoresistance. However, the regulatory mechanisms controlling its dynamic polymerization in response to genotoxic stress remain poorly defined. A major barrier in nuclear actin research is the lack of tools for precise, high-throughput analysis. To systematically investigate nuclear F-actin assembly in DNA damage response, we developed a deep learning pipeline, named nFANet, for high-throughput detection and analysis of nuclear F-actin. Here, using ovarian cancer—a malignancy where chemoresistance is a major clinical obstacle—as a model, we showed that platinum-based chemotherapy robustly induces nuclear F-actin assembly. A subsequent kinome screening, in combination with the application of nFANet, identified the kinase p38α MAPK as a critical upstream regulator of platinum-induced nuclear F-actin assembly. Mechanistically, the p38α MAPK–MK2 signaling pathway promotes formin-mediated nuclear F-actin assembly in response to chemotherapy. Importantly, pharmacological inhibition or genetic knockout of the p38α MAPK–MK2 pathway sensitized ovarian cancer cells to platinum-based therapy. Our work uncovers a key mechanism governing nuclear actin remodeling under genotoxic stress and lays the foundation for identifying a patient subgroup likely to benefit from therapeutic targeting of this pathway.